#gileadsciences — Public Fediverse posts

Gilead Sciences shares dropped 1.5% after hours as the pharmaceutical giant slashed its full-year guidance to a net loss of $0.65-$1.05 per share from previous profit expectations of $8.45-$8.85, citing increased R&D and financing costs from recent major transactions.
#YonhapInfomax #GileadSciences #EarningsGuidance #NetLoss #ResearchAndDevelopment #AfterHoursTrading #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=119467

Gilead Sciences shares dropped 1.5% after hours as the pharmaceutical giant slashed its full-year guidance to a net loss of $0.65-$1.05 per share from previous profit expectations of $8.45-$8.85, citing increased R&D and financing costs from recent major transactions.
#YonhapInfomax #GileadSciences #EarningsGuidance #NetLoss #ResearchAndDevelopment #AfterHoursTrading #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=119467

Gilead Sciences shares dropped 1.5% after hours as the pharmaceutical giant slashed its full-year guidance to a net loss of $0.65-$1.05 per share from previous profit expectations of $8.45-$8.85, citing increased R&D and financing costs from recent major transactions.
#YonhapInfomax #GileadSciences #EarningsGuidance #NetLoss #ResearchAndDevelopment #AfterHoursTrading #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=119467

Gilead Sciences shares dropped 1.5% after hours as the pharmaceutical giant slashed its full-year guidance to a net loss of $0.65-$1.05 per share from previous profit expectations of $8.45-$8.85, citing increased R&D and financing costs from recent major transactions.
#YonhapInfomax #GileadSciences #EarningsGuidance #NetLoss #ResearchAndDevelopment #AfterHoursTrading #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=119467

Yuhan Corporation secures 88.8 billion won contract with Gilead Sciences for additional supply of HIV treatment API, expanding on previous 107.7 billion won deal
#YonhapInfomax #YuhanCorporation #GileadSciences #HIVTreatment #APISupply #PharmaceuticalContract #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64398

Gilead Sciences announces $11 billion additional investment in US amid tariff pressure, aiming to boost domestic manufacturing and R&D capabilities by 2030
#YonhapInfomax #GileadSciences #USInvestment #PharmaceuticalIndustry #TariffPolicies #DomesticProduction #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62277

https://healthnews.pt/.../10a-edicao-programa-gilead.../
A Gilead Sciences anuncia que o prazo para submissão de candidaturas à 10ª edição do Programa Gilead GÉNESE, foi prorrogado até ao próximo dia 30 de setembro de 2024.
#HealthNews #saude #GileadSciences

US government appeals Gilead's trial win in Truvada, Descovy patent fight—Lilly’s Mounjaro helps patients lose more weight than Novo’s Ozempic — FTC report finds PBM power has “dire consequences” —http://bit.ly/w28kSd #gileadsciences #patents #elililly #mounjaro #ozempic #novonordisk #ftc #pbms #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset—BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival —Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority—http://bit.ly/w28kSd #gileadsciences #cancer #antibodydrugconjufate #eisai #bristolmyerssquibb #supremecourt #fda #chevrondoctrine #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Gilead pays $4.3B for CymaBay, primarily for liver disease med—Pharma showed up for the big game — CSL’s ‘big’ post-heart attack drug fails in Phase III trial--http://bit.ly/w28kSd #gileadsciences #mergersandacquisitions #liverdisease #heartattack #clinicaltrials #superbowl #pharmaadvertising #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

6 neuro data readouts to watch in the first half of 2024 —Gilead's Trodelvy fails to extend survival in lung cancer study — Next stage in GSK’s Zantac defense gets underway today --http://bit.ly/w28kSd #neurodegenerativedisease #gileadsciences #clinicaltrials #lungcancer #legal #gsk #zantac #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

6 neuro data readouts to watch in the first half of 2024 —Gilead's Trodelvy fails to extend survival in lung cancer study — Next stage in GSK’s Zantac defense gets underway today --http://bit.ly/w28kSd #neurodegenerativedisease #gileadsciences #clinicaltrials #lungcancer #legal #gsk #zantac #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

📬 Filmemacher machte Millionen mit riskanten Dogecoin-Investments
#Krypto #Kurios #CarlErikRinsch #Dogecoin #GabrielaRosésBentancor #GileadSciences #netflix #RollsRoyce #VacheronConstantin https://tarnkappe.info/artikel/krypto/filmemacher-machte-millionen-mit-riskanten-dogecoin-investments-283913.html

As Biogen's sales flatline, CEO Chris Viehbacher touts progress on Leqembi, Skyclarys and other launches-- Bayer CEO Anderson says 'radical realignment' is underway --Gilead tumbles after unpredictable element drove its 3Q beat -- See more on our front page news http://bit.ly/w28kSd #biogen #pharmaceos #bayer #layoffs #gileadsciences #earnings #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

As Biogen's sales flatline, CEO Chris Viehbacher touts progress on Leqembi, Skyclarys and other launches-- Bayer CEO Anderson says 'radical realignment' is underway --Gilead tumbles after unpredictable element drove its 3Q beat -- See more on our front page news http://bit.ly/w28kSd #biogen #pharmaceos #bayer #layoffs #gileadsciences #earnings #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Can we end AIDS as a public health threat by 2030? Key groups are still left behind and account for an estimated 65% of new HIV infections. In Sub Saharan Africa, 85% of new HIV infections are in young people aged 15-19. But innovation may make the 2030 goal real. I’m chairing a #whs2023 panel supported by #GileadSciences with Florence Riako Anam of GNP+, Janet Dorling of Gilead, Christine Stegling of UNAIDS, Dr Mamadi Yilla of PEPFAR. 10.00 GMT , 17 Oct https://youtube.com/live/JzxsmT4Ph6Y

Ads for brands including #Adobe, #GileadSciences, the #UniversityofMaryland’s #football team, #NewYorkUniversity #LangoneHospital and #NCTA-The #Internet and #Television #Association were run alongside #tweets from the #nazi #account that had garnered hundreds of thousands of views, #CNN observed.